110 related articles for article (PubMed ID: 23078786)
1. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR
Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786
[TBL] [Abstract][Full Text] [Related]
2. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Wei M; Xie C; Huang J; Liu Q; Lai Y
Hematology; 2023 Dec; 28(1):2269509. PubMed ID: 37850613
[TBL] [Abstract][Full Text] [Related]
3. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Pineda-Roman M; Barlogie B; Anaissie E; Zangari M; Bolejack V; van Rhee F; Tricot G; Crowley J
Cancer; 2008 Apr; 112(8):1754-64. PubMed ID: 18300230
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
5. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
Scott EC; Hari P; Sharma M; Le-Rademacher J; Huang J; Vogl D; Abidi M; Beitinjaneh A; Fung H; Ganguly S; Hildebrandt G; Holmberg L; Kalaycio M; Kumar S; Kyle R; Lazarus H; Lee C; Maziarz RT; Meehan K; Mikhael J; Nishihori T; Ramanathan M; Usmani S; Tay J; Vesole D; Wirk B; Yared J; Savani BN; Gasparetto C; Krishnan A; Mark T; Nieto Y; D'Souza A
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1893-1899. PubMed ID: 27496215
[TBL] [Abstract][Full Text] [Related]
6. Increased PD-1 Expression on Circulating T Cells Correlates with Inferior Outcome after Autologous Stem Cell Transplantation.
Richter S; Böttcher M; Stoll A; Zeremski V; Völkl S; Mackensen A; Ekici AB; Jacobs B; Mougiakakos D
Transplant Cell Ther; 2024 Jun; 30(6):628.e1-628.e9. PubMed ID: 38460727
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation.
Pasvolsky O; Wang Z; Milton DR; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Tang G; Kebriaei P; Aljawai Y; Khan HN; Lee HC; Ye C; Patel KK; Thomas SK; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Blood Cancer J; 2024 May; 14(1):82. PubMed ID: 38760362
[TBL] [Abstract][Full Text] [Related]
8. Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis.
Li H; Zheng Y; Gao K; Tian C
Hematology; 2024 Dec; 29(1):2343164. PubMed ID: 38651865
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation.
Wood WA; Deal AM; Abernethy A; Basch E; Battaglini C; Kim YH; Whitley J; Shatten C; Serody J; Shea T; Reeve BB
Biol Blood Marrow Transplant; 2013 Mar; 19(3):450-9. PubMed ID: 23253558
[TBL] [Abstract][Full Text] [Related]
10. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.
D'Souza A; Pasquini M; Logan B; Giralt S; Krishnan A; Antin J; Howard A; Goodman S; Qazilbash M; Knust K; Sahebi F; Weisdorf D; Vesole D; Stadtmauer E; Maloney D; Hari P
Br J Haematol; 2017 Sep; 178(5):816-819. PubMed ID: 27292583
[No Abstract] [Full Text] [Related]
11. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk.
Corre J; Montes L; Martin E; Perrot A; Caillot D; Leleu X; Belhadj K; Facon T; Hulin C; Mohty M; Fontan J; Macro M; Brechignac S; Jaccard A; Stoppa AM; Orsini-Piocelle F; Adiko D; Voillat L; Keddar F; Barry M; Demarquette H; Certain MN; Plantier I; Roussel M; Hébraud B; Filleron T; Attal M; Avet-Loiseau H
Haematologica; 2020 Sep; 105(9):e480-483. PubMed ID: 33054068
[No Abstract] [Full Text] [Related]
12. HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation.
Dickter JK; Aribi A; Cardoso AA; Gianella S; Gendzekhadze K; Li S; Feng Y; Chaillon A; Laird GM; Browning DL; Ross JA; Nanayakkara DD; Puing A; Stan R; Lai LL; Chang S; Kidambi TD; Thomas S; Al Malki MM; Nakamura R; Alvarnas J; Taplitz RA; Dadwal SS; Forman SJ; Zaia JA
N Engl J Med; 2024 Feb; 390(7):669-671. PubMed ID: 38354149
[No Abstract] [Full Text] [Related]
13. The incidence of translocation t(11;14) among patients with multiple myeloma in a single clinic.
Jew S; Goldwater MS; Bujarski S; Regidor B; Emamy-Sadr M; Swift R; Eades B; Said J; Berenson JR
Am J Clin Pathol; 2024 Jan; 161(1):16-23. PubMed ID: 37611113
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.
Knop S; Engelhardt M; Liebisch P; Meisner C; Holler E; Metzner B; Peest D; Kaufmann M; Bunjes D; Straka C; Fischer T; Sezer O; Hentrich M; Ostermann H; Bassermann F; Hess G; Hertenstein B; Freund M; Kropff M; Schmidt CA; Wolf HH; Jung W; Frickhofen N; Mielke S; Bargou RC; Maschmeyer G; Svaldi M; Langer CH; Gramatzki M; Hebart H; Kanz L; Einsele H;
Leukemia; 2019 Nov; 33(11):2710-2719. PubMed ID: 31462732
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure?
Kaloyannidis P; Apostolidis J
Curr Treat Options Oncol; 2021 Jun; 22(8):65. PubMed ID: 34110512
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome after allogeneic stem cell transplantation in multiple myeloma.
Luoma S; Silvennoinen R; Rauhala A; Niittyvuopio R; Martelin E; Lindström V; Heiskanen J; Volin L; Ruutu T; Nihtinen A
Ann Hematol; 2021 Jun; 100(6):1553-1567. PubMed ID: 33866396
[TBL] [Abstract][Full Text] [Related]
17. Boosting Immunity against Multiple Myeloma.
Lopes R; Ferreira BV; Caetano J; Barahona F; Carneiro EA; João C
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799565
[TBL] [Abstract][Full Text] [Related]
18. Role of Stem Cell Transplantation in Multiple Myeloma.
Devarakonda S; Efebera Y; Sharma N
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670709
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic Transplantation in Multiple Myeloma-Does It Still Have a Place?
Gahrton G; Iacobelli S; Garderet L; Yakoub-Agha I; Schönland S
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32664274
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
